31P MR Spectroscopy in Assessment of Response to Antiviral Therapy for Hepatitis C Virus–Related Liver Disease
Adrian K. P. Lim1,
Nayna Patel1,2,
Gavin Hamilton1,2,
Kailash Mylvahan1,2,
Yu-Ting Kuo1,3,
Robert D. Goldin4 and
Simon D. Taylor-Robinson1,2
1 Department of Imaging Sciences, Faculty of Medicine, Imperial College London,
Robert Steiner MRI Unit, MRC Clinical Sciences Centre, Hammersmith Hospital,
Du Cane Rd., London W12 0HS, United Kingdom.
2 Liver Unit, Division of Medicine, Imperial College London, St. Mary's
Hospital, London, United Kingdom.
3 Department of Medical Imaging, Faculty of Medicine, School of Medicine,
Kaohsiung Medical University, Taiwan.
4 Department of Histopathology, Faculty of Medicine, Imperial College London,
St. Mary's Hospital, London, United Kingdom.

View larger version (20K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 1 —40-year-old woman with cirrhosis secondary to hepatitis C
virus infection. Graph shows change in 31P MR spectra 1 year after
treatment. Patient successfully cleared virus after antiviral treatment. Red
indicates baseline spectrum; blue, spectrum 12 months after treatment. PME =
phosphomonoester, PDE = phosphodiester.
|
|

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Copyright © 2007 by the American Roentgen Ray Society.